查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095136

長效避孕藥市場－2026-2032年全球市場預測

Long-acting Contraception Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，長效避孕藥市場規模將達到 118.7 億美元，年複合成長率為 8.29%。

主要市場統計數據
基準年 2025 68億美元
預計年份：2026年 73.5億美元
預測年份 2032 118.7億美元
複合年成長率 (%) 8.29%

長效避孕法是指在開始使用後只需極少用戶干預即可長期有效預防懷孕的高效避孕方法，包括子宮內避孕器（IUD）、皮下植入和注射避孕藥。這些方法在公共衛生策略中發揮核心作用，因為它們減少了對每日堅持使用的依賴，支持了生育自主權，並滿足了現代避孕方面未被滿足的需求。世界各地的衛生機構一致認為，長效可逆避孕是最有效的可逆避孕方法之一，其在典型使用中的有效性顯著高於依賴使用者持續努力的短效避孕方法。需求成長的促進因素包括：計劃生育服務可近性的提高、對避孕選擇的認知不斷增強、產後和流產後避孕措施的整合，以及對青少年和青年人生殖健康的日益重視。然而，其廣泛應用仍受到經濟負擔、醫護人員培訓、諮詢品質、文化接受度、供應穩定性和政策支持等因素的影響。在這個不斷變化的環境中，參與醫療保健服務、採購、數位健康和​​公共計畫的相關人員優先考慮公平獲取、知情選擇和以患者為中心的避孕護理。

長效避孕領域的變革性變化

長效避孕的格局正在重塑，其關注點正從單純的產品供應轉向以權利為基礎、以個人為中心的避孕生態系統。醫療衛生系統正在加速將避孕器（IUD）、植入和注射避孕藥納入基層醫療、孕產婦保健、青少年保健和社區服務，從而改善專科機構以外的就醫途徑。支持全民健康覆蓋（UHC）、保險報銷和公共資助的計劃生育項目的政策改革正在減少與費用相關的障礙。此外，分工模式使訓練有素的護理人員、助產士和社區衛生工作者能夠擴大服務範圍，即使在醫生資源有限的地區也是如此。另一個重大轉變是更重視避孕諮詢的質量，強調知情同意、副作用管理、持續支持以及避免強制使用目標。此外，鑑於供應鏈中斷暴露了採購、某些注射藥物的低溫運輸要求以及最後一公里配送的脆弱性，供應鏈韌性已成為一項策略重點。同時，遠端醫療、數位預約系統、電子健康記錄和行動教育工具正在改善後續服務、支持更換避孕方法以及創造需求，尤其是在尋求敏感生殖健康資訊的年輕人中。

人工智慧（AI）對長效避孕藥的累積影響

人工智慧 (AI) 正透過決策支援、供應鏈最佳化、藥物安全監測和個人化生殖健康服務，開始對長效避孕產生影響。在臨床環境中，AI 工具可以幫助醫護人員整理病患病歷、根據既定的醫學合格標準識別禁忌症，並推薦合適的諮商主題。然而，最終決策仍必須由臨床醫師主導並充分考慮病患資訊。在公共衛生領域，預測分析可用於預測庫存短缺、最佳化避孕器、植入式避孕器和注射藥物的分配，並提高各醫療機構訓練有素的醫護人員的部署。 AI 還可以透過分析匿名化的醫療記錄和報告模式來加強不利事件監測，從而幫助及早發現安全訊號和服務品質差異。為了促進患者參與，多語言聊天機器人和移動工具可以提供一般健康教育、預約提醒和副作用指導，但這些工具的設計必須能夠保護隱私、避免偏見，並明確區分教育和診斷。人工智慧的累積影響取決於其是否符合倫理管治、檢驗的臨床內容、公平的資料呈現、網路安全和生殖權利原則。這確保了數位創新能夠拓展而非限制或束縛人們的選擇。

關於長效避孕的關鍵區域見解

亞太地區避孕途徑的可及性呈現出多樣化的特徵。中國、印度、日本、澳洲和韓國等國家在公共資金投入、醫療服務提供者能力以及對子宮內避孕器、植入式避孕器和注射式避孕器的文化接受度方面存在顯著差異。儘管該地區龐大的育齡人口、政府支持的計劃生育計畫以及不斷擴展的數位醫療基礎設施正在促進避孕途徑的普及，但農村地區的服務差距和諮詢品質的差異仍然是重要的障礙。在歐洲，儘管有法律規範、廣泛的生殖健康服務和健全的公共衛生基礎設施，但各國的避孕偏好各不相同，並受到報銷模式、醫療服務提供者實踐和國家健康政策的影響。在北美，長效可逆避孕方法已廣泛納入基層醫療、婦產科和產後護理，受益於完善的臨床指南、保險覆蓋途徑和強大的醫療服務提供者網路。然而，經濟負擔、各州政策差異以及缺乏醫療服務的社區之間的差距仍然影響著避孕藥具的可近性。在拉丁美洲，儘管一些國家擁有強力的公共部門計劃生育舉措，並且人們對植入和避孕器器的認知度也在不斷提高，但醫療衛生系統的碎片化、採購限制以及社會文化障礙仍然會阻礙避孕藥具的可及性。非洲仍然是獲得長效避孕藥具的關鍵地區，公共衛生計畫和捐助者支持的採購活動正在擴大許多國家植入和注射避孕器的供應。然而，醫療服務提供者短缺、庫存不穩定、農村地區難以進入以及錯誤訊息的傳播仍然影響避孕藥具的使用率和持續使用率。在中東，隨著都市區醫療衛生服務和孕產婦保健計畫的擴展，現代避孕服務的使用率正在逐步提高。然而，關於分娩、隱私和諮詢服務的相關規範仍然會影響需求。

來自北約、七國集團、金磚國家、歐盟、東協和海灣合作理事會等主要組織的見解

在北約國家，長效避孕措施的可近性受到與北美和歐洲醫療保健體系許多通用的影響。在這些地區，公共保險體系、隱私法規、軍民醫療保健途徑以及循證性與生殖健康標準都會影響服務提供；然而，成員國之間的差異仍然影響著實際的可及性。七國集團（G7）國家普遍受益於先進的醫療保健基礎設施、正式的臨床指南、完善的報銷機制和健全的藥物安全監測系統，使其成為改善與長效可逆避孕相關的諮詢品質、產後服務以及青少年生殖健康服務的關鍵中心。金磚國家在長效避孕方面呈現多種趨勢，從大規模公共計畫和國內醫療產品生產能力到收入和地理差異導致的可及性差距。歐盟（EU）擁有相對成熟的生殖健康政策環境，這得益於監管協調、許多成員國的公共醫療保險覆蓋以及完善的臨床指南。然而，保險報銷和避孕偏好在各國之間仍存在差異。在東協地區，隨著初級衛生保健體系的擴展、孕產婦保健舉措和國家計劃生育計畫的推進，長效避孕方法的使用率正在提高；然而，由於資金籌措能力、農村基礎設施和醫護人員培訓等方面的差異，各成員國之間的可及性存在差異。在海灣合作理事會國家，婦女健康服務、數位醫療的普及以及私營部門對生殖醫學的關注度都在不斷提高，而避孕選擇則受到文化規範、醫生諮詢和都市區醫療服務可及性的影響。

各國長效避孕的關鍵見解

在中國，子宮內避孕器（IUD）的使用歷史悠久，計劃生育基礎設施大規模；然而，由於人口政策的轉變和生育偏好的變化，目前的需求正在改變。在美國，子宮內避孕器和植入式避孕器在臨床上被廣泛認可為高效的避孕方法，其使用受到保險覆蓋範圍、第十條援助服務、醫療補助政策和州級生殖健康法規的影響。與許多高所得國家相比，日本的避孕方式較為保守，其普及程度受到監管歷史、醫師診療習慣和病人意識的影響。在印度，現代避孕方法的推廣透過公共衛生計畫不斷擴大，注射避孕藥、產後子宮內避孕器和社區諮詢發揮重要作用，但知情選擇和醫護人員培訓仍然是重中之重。德國、法國、義大利和西班牙均採用受監管的歐洲醫療保健體系，在這些體系中，報銷規則、醫生諮詢和患者偏好都會影響避孕選擇，子宮內避孕器（IUD）在臨床實踐中應用廣泛。在英國，國家醫療服務體系（NHS）和性健康診所在提供植入、子宮內避孕器和注射避孕藥方面發揮著重要作用，但服務能力和預約情況可能會影響使用率。在澳大利亞，透過基層醫療和專科服務系統性地提供生殖醫學服務，臨床指南推薦使用長效可逆避孕方法，但農村地區的醫療服務可近性和醫護人員培訓仍然是重大挑戰。韓國擁有先進的醫療基礎設施和數位醫療發展，但避孕行為受社會規範、生育率趨勢以及病患與醫護人員溝通的影響。在加拿大，各省的醫療保健系統和公共衛生計畫為避孕提供支持，但保險覆蓋範圍和自付費用可能因省份和人口而異。在俄羅斯，民眾可透過公共和私人管道獲得避孕服務，但其使用情況受醫療服務提供者的實踐、意識以及對荷爾蒙避孕和子宮內避孕器的態度影響。在巴西和墨西哥，公共計劃生育服務體系完善，獲得長效避孕措施取決於公共採購、醫療服務提供者的保障以及與婦幼保健項目的整合。

為行業領導者提供的實用建議

產業領導者應優先考慮公平取得、高品質諮詢和穩健的服務體系，以促進長效避孕方法的普及。產品和服務策略必須符合國際醫學規範、國家生殖健康指南以及以病人為中心的知情選擇原則。由於服務品質直接影響患者的持續使用和信任度，相關人員應投資培訓醫護人員，使其掌握避孕方法的插入/取出、副作用諮詢和避孕方法轉換等方面的知識。採購和分銷團隊應透過加強需求計劃、在適當情況下實現供應管道多元化以及提高整個末端物流的透明度來減少缺貨情況。數位健康的投資應著重於隱私權保護教育、預約安排、追蹤提醒和多語言支持，而非指令性決策。與公共衛生機構、社區組織和基層醫療網路建立合作關係，可以改善青少年、產後患者、農村居民和弱勢群體獲得避孕服務的途徑。此外，領導者需要加強藥物安全監測和真實世界數據（REW）系統，以監測安全性、持續使用、滿意度和停藥原因，從而在不損害生殖自主權的前提下，實現情境化服務改善。

調查方法

本執行摘要採用基於檢驗的公共衛生、臨床、監管和政策資訊來源的二手調查方法編寫而成。證據包括國際生殖健康指南、國家計劃生育政策、醫療合格標準、同行評審文獻、公共衛生計畫文件、監管資訊和人口健康指標。本分析著重於已驗證的質性研究和檢驗見解，而非市場規模估算、預測、市場規模計算、市場佔有率或預測。透過檢視醫療保健系統結構、避孕藥具可近性、報銷和獲取機制、醫療服務提供者能力、公共部門計畫以及已記錄的知情避孕選擇障礙，整合了區域、群體和國家層面的具體觀點。調查方法優先考慮跨可靠資訊來源的檢驗，以確保一致性，避免宣傳性聲明，並著重於對醫療保健相關人員、政策制定者、採購團隊、服務提供者以及在長效避孕生態系統中運營的數位健康創新者俱有可操作性的影響。

結論

長效避孕是現代醫療保健的基石，它不僅能有效、方便地預防懷孕，還能支持更廣泛的目標，例如孕產婦健康、青少年健康和生殖自主權。該領域正從以產品為中心的模式轉向以權利為基礎的綜合服務模式轉變，強調可近性、高品質諮詢、安全監測和持續照護。由於政策框架、資金籌措、醫護人員培訓、文化態度和供應鏈績效等方面的差異，區域和國家層面的差距仍然顯著。人工智慧和數位醫療有潛力改善教育、物流、後續服務和證據生成，但前提是必須輔以強力的隱私保護、檢驗的內容以及防止偏見和脅迫的安全網。對於行業領導者而言，最具永續的機會在於加強以患者為中心的護理路徑，支持訓練有素的醫護人員，改善可靠的供應鏈，並與公共衛生系統合作，以確保長效避孕仍然可及、自願，並與知情的生殖選擇相一致。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 長效避孕藥市場：依產品類型分類

  • 避孕器
  • 避孕植入
  • 注射式避孕藥
  • 陰道環

第8章：長效避孕藥市場：依荷爾蒙類型分類

  • 荷爾蒙避孕藥
  • 非荷爾蒙避孕藥

第9章：長效避孕藥市場：依使用時間分類

  • 有效期限為3年的避孕藥
  • 5年有效避孕藥
  • 有效期限長達10年的避孕藥

第10章：長效避孕藥市場：依給藥方式分類

  • 避孕器
  • 皮下注射
  • 肌肉內部
  • 陰道內部
  • 經皮吸收

第11章 長效避孕藥市場：依最終用戶分類

  • 醫院
  • 婦科診所
  • 計劃生育診所
  • 社區健康中心
  • 門診手術中心
  • 居家照護環境

第12章 長效避孕藥市場：依通路分類

  • 離線
  • 線上

第13章 長效避孕藥市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章 長效避孕藥市場：依類別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 長效避孕藥市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Bayer AG
  • Besins Healthcare
  • Changzhou Medical Bioengineering Co., Ltd.
  • CTTQ Pharmaceutical Group Co., Ltd.
  • Cupid Limited
  • Eurogine SL
  • Fuji Latex Co., Ltd.
  • Guangzhou Tianhe Medical Technology Co., Ltd.
  • Innova Medical Oy
  • Laboratoire 7 MED
  • Mankind Pharma Limited
  • Merck KGaA
  • Mona Lisa NV
  • Ningbo Jiulong Medical Instruments Co., Ltd.
  • OCON Healthcare Ltd.
  • Organon & Co.
  • Pregna International Limited
  • Reckitt Benckiser Group plc
  • Rusan Pharma Ltd.
  • Shanghai Dahua Pharmaceutical Co., Ltd.
  • Shenzhen JCR Medical Technology Ltd.
  • SMB Corporation of India
  • Teva Pharmaceutical Industries Ltd.
  • Theramex HQ UK Limited
  • TherapeuticsMD, Inc.
  • UMEDO Co., Ltd.
  • Viatris Inc.
  • Zhejiang Aimake Medical Technology Co., Ltd.
Product Code: MRR-563BF1FD02BB

The Long-acting Contraception Market is projected to grow by USD 11.87 billion at a CAGR of 8.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.80 billion
Estimated Year [2026] USD 7.35 billion
Forecast Year [2032] USD 11.87 billion
CAGR (%) 8.29%

Long-acting contraception refers to highly effective contraceptive methods that provide pregnancy prevention for extended periods with minimal user action after initiation, including intrauterine devices, contraceptive implants, and injectable contraceptives. These methods are central to public health strategies because they reduce reliance on daily adherence, support reproductive autonomy, and help address unmet need for modern contraception. Global health authorities consistently recognize long-acting reversible contraception as among the most effective reversible options, with typical-use effectiveness that is substantially higher than short-acting user-dependent methods. Demand is shaped by expanding access to family planning services, growing awareness of method choice, postpartum and post-abortion contraception integration, and increased emphasis on adolescent and young adult reproductive health. At the same time, adoption remains influenced by affordability, provider training, counseling quality, cultural acceptance, supply continuity, and policy support. In this evolving landscape, stakeholders across healthcare delivery, procurement, digital health, and public programs are prioritizing equitable access, informed choice, and patient-centered contraceptive care.

Transformative Shifts in the Long-acting Contraception Landscape

The long-acting contraception landscape is being reshaped by a shift from product availability alone toward rights-based, person-centered contraceptive ecosystems. Health systems are increasingly integrating intrauterine devices, implants, and injectables into primary care, maternal health, adolescent health, and community-based services, improving access beyond specialized facilities. Policy reforms supporting universal health coverage, insurance reimbursement, and publicly funded family planning programs are helping reduce cost-related barriers, while task-sharing approaches allow trained nurses, midwives, and community health workers to expand service reach where physician availability is limited. Another major transformation is the rising focus on contraceptive counseling quality, with emphasis on informed consent, side-effect management, continuation support, and avoidance of coercive uptake targets. Supply-chain resilience has also become a strategic priority following disruptions that exposed vulnerabilities in procurement, cold-chain requirements for some injectables, and last-mile distribution. Concurrently, telehealth, digital appointment scheduling, electronic medical records, and mobile education tools are improving follow-up, method switching support, and demand generation, especially among younger populations seeking confidential reproductive health information.

Cumulative Impact of Artificial Intelligence on Long-acting Contraception

Artificial intelligence is beginning to influence long-acting contraception through decision support, supply-chain optimization, pharmacovigilance, and personalized reproductive health engagement. In clinical settings, AI-enabled tools can support providers by organizing patient histories, identifying contraindications based on established medical eligibility criteria, and prompting appropriate counseling topics, while final decisions must remain clinician-led and consent-based. In public health operations, predictive analytics can help anticipate stockouts, optimize distribution of intrauterine devices, implants, and injectables, and improve allocation of trained providers across facilities. AI can also strengthen adverse event monitoring by analyzing anonymized health records and reporting patterns, supporting earlier detection of safety signals or service-quality gaps. For patient engagement, multilingual chatbots and mobile tools can provide general education, appointment reminders, and side-effect guidance, although they must be designed to protect privacy, avoid bias, and clearly separate education from diagnosis. The cumulative impact of AI will depend on ethical governance, validated clinical content, equitable data representation, cybersecurity, and alignment with reproductive rights principles to ensure that digital innovation expands choice rather than directing or restricting it.

Key Regional Insights for Long-acting Contraception

Asia-Pacific is characterized by diverse contraceptive access patterns, with countries such as China, India, Japan, Australia, and South Korea differing widely in public financing, provider capacity, and cultural acceptance of intrauterine devices, implants, and injectables. The region's large reproductive-age population, government-supported family planning programs, and expanding digital health infrastructure support broader access, while rural service gaps and uneven counseling quality remain important barriers. Europe demonstrates high regulatory oversight, broad reproductive health services, and strong public health infrastructure, though method preferences vary across countries and are shaped by reimbursement models, provider practice patterns, and national sexual health policies. North America benefits from established clinical guidelines, insurance coverage pathways, and strong provider networks, with long-acting reversible contraception commonly integrated into primary care, obstetrics and gynecology, and postpartum services; however, affordability, state-level policy variation, and disparities among underserved communities continue to influence access. Latin America has strong public-sector family planning initiatives in several countries and growing awareness of implants and intrauterine devices, yet access can be affected by fragmented health systems, procurement constraints, and sociocultural barriers. Africa remains a critical region for long-acting contraception access, as public health programs and donor-supported procurement have expanded availability of implants and injectables in many countries; nevertheless, provider shortages, stock reliability, rural access, and misinformation continue to affect uptake and continuation. The Middle East shows gradual growth in modern contraceptive service adoption, supported by urban healthcare expansion and maternal health programs, while norms around fertility, privacy, and counseling access influence demand.

Key Group Insights Across NATO, G7, BRICS, EU, ASEAN, and GCC

Across NATO, long-acting contraception access is shaped by the group's broad overlap with North American and European health systems, where service delivery is influenced by public coverage models, privacy regulations, military and civilian healthcare pathways, and evidence-based sexual and reproductive health standards, while member-to-member variation continues to shape real-world access. G7 countries generally benefit from advanced healthcare infrastructure, formal clinical guidelines, established reimbursement mechanisms, and robust pharmacovigilance systems, making them important centers for quality improvement in long-acting reversible contraception counseling, postpartum access, and adolescent reproductive health services. BRICS countries collectively represent a broad spectrum of long-acting contraception dynamics, from large-scale public programs and domestic healthcare manufacturing capacity to uneven access across income groups and geographies. The European Union provides a comparatively mature policy environment for reproductive health, supported by regulatory harmonization, public healthcare coverage in many member states, and established clinical guidance; however, reimbursement and method preferences remain country-specific. Within ASEAN, long-acting contraception adoption is supported by expanding primary healthcare systems, maternal health initiatives, and national family planning programs, although access differs across member states due to financing capacity, rural infrastructure, and provider training. The GCC countries are witnessing rising attention to women's health services, digital healthcare delivery, and private-sector reproductive care, with contraceptive choices shaped by cultural norms, physician counseling, and urban healthcare access.

Key Country Insights for Long-acting Contraception

China has a long history of intrauterine device use and large-scale family planning infrastructure, while current demand is changing alongside demographic policy shifts and evolving reproductive preferences. The United States has strong clinical recognition of intrauterine devices and implants as highly effective contraception, with access influenced by insurance coverage, Title X-supported services, Medicaid policy, and state-level reproductive health rules. Japan has a more conservative contraceptive method mix compared with many high-income countries, with adoption influenced by regulatory history, physician practice, and patient awareness. India continues to expand modern contraception through public health programs, with injectables, postpartum intrauterine contraception, and community-based counseling playing important roles, though informed choice and provider training remain central priorities. Germany, France, Italy, and Spain operate within regulated European healthcare systems where reimbursement rules, physician counseling, and patient preferences shape method selection, and where intrauterine contraception is well established in clinical practice. In the United Kingdom, national health services and sexual health clinics play a major role in access to implants, intrauterine contraception, and injectables, while service capacity and appointment availability can influence utilization. Australia provides structured reproductive healthcare access through primary care and specialist services, with long-acting reversible contraception promoted in clinical guidance, while rural access and provider insertion training remain relevant. South Korea has advanced healthcare infrastructure and digital health readiness, but contraceptive behavior is shaped by social norms, fertility trends, and patient-provider communication. Canada supports contraception through provincial healthcare structures and public health programs, though coverage and out-of-pocket costs can vary by province and population group. Russia has contraceptive access through public and private channels, but uptake patterns are influenced by provider practices, awareness, and attitudes toward hormonal and intrauterine methods. Brazil and Mexico have established public family planning services, with long-acting contraception access linked to public procurement, provider availability, and integration with maternal health and adolescent health programs.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize equitable access, high-quality counseling, and resilient delivery systems to strengthen long-acting contraception adoption. Product and service strategies should align with international medical eligibility criteria, national reproductive health guidelines, and patient-centered informed choice principles. Stakeholders should invest in provider training for insertion, removal, side-effect counseling, and method switching, as service quality directly affects continuation and trust. Procurement and distribution teams should strengthen demand planning, diversify supply channels where appropriate, and improve visibility across last-mile logistics to reduce stockouts. Digital health investments should focus on privacy-preserving education, appointment navigation, follow-up reminders, and multilingual support rather than directive decision-making. Partnerships with public health agencies, community organizations, and primary care networks can improve access for adolescents, postpartum patients, rural populations, and underserved communities. Leaders should also strengthen pharmacovigilance and real-world evidence systems to monitor safety, continuation, satisfaction, and reasons for discontinuation, enabling responsive service improvement without compromising reproductive autonomy.

Research Methodology

This executive summary is developed using a secondary research methodology grounded in verified public health, clinical, regulatory, and policy sources. Evidence inputs include international reproductive health guidance, national family planning policies, medical eligibility criteria, peer-reviewed literature, public health program documentation, regulatory information, and demographic health indicators. The analysis emphasizes validated qualitative and evidence-based insights rather than market estimation, market sizing, market share, or forecasting. Regional, group, and country perspectives are synthesized by reviewing health system structures, contraceptive method availability, reimbursement and access mechanisms, provider capacity, public-sector programming, and documented barriers to informed contraceptive choice. The methodology prioritizes triangulation across credible sources to ensure consistency, avoids promotional claims, and focuses on actionable implications for healthcare stakeholders, policymakers, procurement teams, service providers, and digital health innovators operating in the long-acting contraception ecosystem.

Conclusion

Long-acting contraception is a critical pillar of modern reproductive healthcare, offering effective, low-maintenance pregnancy prevention while supporting broader goals in maternal health, adolescent health, and reproductive autonomy. The sector is evolving from a product-centered model toward integrated, rights-based service delivery that values access, counseling quality, safety monitoring, and continuity of care. Regional and country-level differences remain substantial, driven by policy frameworks, financing, provider training, cultural attitudes, and supply-chain performance. Artificial intelligence and digital health can improve education, logistics, follow-up, and evidence generation, but only when implemented with strong privacy protections, validated content, and safeguards against bias or coercion. For industry leaders, the most sustainable opportunities lie in strengthening patient-centered care pathways, supporting trained providers, improving reliable supply, and collaborating with public health systems to ensure that long-acting contraception remains accessible, voluntary, and aligned with informed reproductive choice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Long-acting Contraception Market, by Product Type

  • 7.1. Introduction
  • 7.2. Intrauterine Devices
  • 7.3. Contraceptive Implants
  • 7.4. Injectable Contraceptives
  • 7.5. Vaginal Rings

8. Long-acting Contraception Market, by Hormone Type

  • 8.1. Introduction
  • 8.2. Hormonal Contraceptives
  • 8.3. Non-Hormonal Contraceptives

9. Long-acting Contraception Market, by Duration of Effectiveness

  • 9.1. Introduction
  • 9.2. 3-Year Contraceptives
  • 9.3. 5-Year Contraceptives
  • 9.4. 10-Year Contraceptives

10. Long-acting Contraception Market, by Delivery Mode

  • 10.1. Introduction
  • 10.2. Intrauterine
  • 10.3. Subdermal
  • 10.4. Intramuscular
  • 10.5. Vaginal
  • 10.6. Transdermal

11. Long-acting Contraception Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals
  • 11.3. Gynecology Clinics
  • 11.4. Family Planning Clinics
  • 11.5. Community Health Centers
  • 11.6. Ambulatory Surgical Centers
  • 11.7. Homecare Settings

12. Long-acting Contraception Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline
  • 12.3. Online

13. Long-acting Contraception Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Long-acting Contraception Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Long-acting Contraception Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Bayer AG
  • 17.2. Besins Healthcare
  • 17.3. Changzhou Medical Bioengineering Co., Ltd.
  • 17.4. CTTQ Pharmaceutical Group Co., Ltd.
  • 17.5. Cupid Limited
  • 17.6. Eurogine S.L.
  • 17.7. Fuji Latex Co., Ltd.
  • 17.8. Guangzhou Tianhe Medical Technology Co., Ltd.
  • 17.9. Innova Medical Oy
  • 17.10. Laboratoire 7 MED
  • 17.11. Mankind Pharma Limited
  • 17.12. Merck KGaA
  • 17.13. Mona Lisa N.V.
  • 17.14. Ningbo Jiulong Medical Instruments Co., Ltd.
  • 17.15. OCON Healthcare Ltd.
  • 17.16. Organon & Co.
  • 17.17. Pregna International Limited
  • 17.18. Reckitt Benckiser Group plc
  • 17.19. Rusan Pharma Ltd.
  • 17.20. Shanghai Dahua Pharmaceutical Co., Ltd.
  • 17.21. Shenzhen JCR Medical Technology Ltd.
  • 17.22. SMB Corporation of India
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Theramex HQ UK Limited
  • 17.25. TherapeuticsMD, Inc.
  • 17.26. UMEDO Co., Ltd.
  • 17.27. Viatris Inc.
  • 17.28. Zhejiang Aimake Medical Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LONG-ACTING CONTRACEPTION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL LONG-ACTING CONTRACEPTION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL LONG-ACTING CONTRACEPTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRACEPTIVE IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTRACEPTIVE IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRACEPTIVE IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VAGINAL RINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VAGINAL RINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VAGINAL RINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-HORMONAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL 3-YEAR CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL 3-YEAR CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL 3-YEAR CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL 5-YEAR CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL 5-YEAR CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL 5-YEAR CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL 10-YEAR CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL 10-YEAR CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL 10-YEAR CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAUTERINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAUTERINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAUTERINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUBDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUBDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SUBDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VAGINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VAGINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VAGINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FAMILY PLANNING CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FAMILY PLANNING CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FAMILY PLANNING CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 123. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 124. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 130. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 180. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 181. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 187. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 188. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 194. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 195. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 208. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 209. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 215. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 216. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 222. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 223. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 229. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 230. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 243. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 244. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF EFFECTIVENESS, 2018-2032 (USD MILLION)
  • TABLE 264. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 265. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 268. GLOBAL LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025